RT Journal Article
SR Electronic
T1 Bevacizumab with Single-agent Chemotherapy in Previously Treated Non-squamous Non-small-cell Lung Cancer: Phase II Study
JF In Vivo
JO In Vivo
FD International Institute of Anticancer Research
SP 1155
OP 1160
DO 10.21873/invivo.11358
VO 32
IS 5
A1 YAMAGUCHI, KAKUHIRO
A1 MASUDA, TAKESHI
A1 FUJITAKA, KAZUNORI
A1 MIWATA, KEI
A1 SAKAMOTO, SHINJIRO
A1 HORIMASU, YASUSHI
A1 HAMAI, KOSUKE
A1 MIYAMOTO, SHINTARO
A1 NAKASHIMA, TAKU
A1 OKAMOTO, YOHEI
A1 IWAMOTO, HIROSHI
A1 ISHIKAWA, NOBUHISA
A1 MIYATA, YOSHIHIRO
A1 OKADA, MORIHITO
A1 HAMADA, HIRONOBU
A1 HATTORI, NOBORU
YR 2018
UL http://iv.iiarjournals.org/content/32/5/1155.abstract
AB Aim: This study was designed to evaluate the efficacy and tolerability of bevacizumab with docetaxel or pemetrexed in previously treated patients with non-squamous non-small cell lung cancer. Patients and Methods: This study enrolled patients who had received at least one chemotherapy regimen, regardless of prior use of bevacizumab. Combinations of docetaxel or pemetrexed were chosen by attending physicians. The primary endpoint was progression-free survival, and secondary endpoints were safety, disease control rate, and overall survival. Results: Thirty patients from two institutions were eligible. The median progression-free and overall survival were 5.0 months (95% confidence interval=3.2-8.8 months) and 15.8 months (95% confidence interval=10.5-19.6 months), respectively. The disease control rate was 66.7%. Treatments were well tolerated, but the development rate of osteonecrosis of the jaw was 10%. Conclusion: Addition of bevacizumab in a salvage setting might be effective, but the development of osteonecrosis of the jaw needs to be monitored.